Early Outcomes of Sutureless Aortic Valve Replacement With the Perceval S Bioprosthesis.

Background: Sutureless aortic valve replacement (SU-AVR)offers an alternative to traditional aortic valve replacement (AVR)and is becoming widely performed in many hospitals. The aim of the current study was to evaluate the early experience in SU-AVR with the Perceval S bioprosthesis at Monash Medical Centre. Method(s): Fifty-two (52)patients who underwent SU-AVR were retrospectively analysed (mean age: 74.8 +/- 6.5 years). Data regarding preoperative and operative details, hospital stay, postoperative outcomes within 30 days after surgery, re-admissions and longer term echocardiographic data were collected from the relevant hospital databases. Result(s): In isolated SU-AVR, the mean aortic cross-clamp and cardiopulmonary bypass times were 48.8 and 67.8 minutes, respectively. There were no deaths within 30 days after surgery. Rhythm disturbances developed in 46.2% of patients, with atrial fibrillation (32.7%)and heart block (9.6%)being most common. Mean and peak transaortic gradients reduced from 46.2 and 77.9 mmHg preoperatively, to 10.7 and 19.7 mmHg at 12 months postoperatively, respectively. Conclusion(s): The absence of early mortality and the satisfactory clinical and haemodynamic results demonstrated the overall safety and efficacy of the Perceval S valve. Although sutureless valves seem to be a promising alternative to traditional sutured valves, the high rate of new postoperative rhythm disturbances, particularly heart block, is potentially a concern with SU-AVR.Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS)and the Cardiac Society of Australia and New Zealand (CSANZ)